TEVA

Oct 20, 8:07 AMTeva and Sanofi report positive 44‑week Phase 2b extension data for TL1A antibody duvakitug in ulcerative colitis and Crohn’s disease

Peers: VTRS AMRX RDY NBIX ALVO PRGO OGN PFE LLY ABBV

| Held by: IEFA EFA EIS WCMI EFG IXUS IXUS SPDW PPH IDVO

Scroll to Statements

Index	-
Market Cap	47.60B
Enterprise Value	60.83B
Income	706.00M
Sales	17.34B
Book/sh	6.65
Cash/sh	3.14
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	Nov 27, 2017
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	33346
IPO	Feb 16, 1982

P/E	68.11
Forward P/E	13.26
PEG	2.40
P/S	2.75
P/B	6.14
P/C	13.02
P/FCF	17.45
EV/EBITDA	14.30
EV/Sales	3.51
Quick Ratio	0.67
Current Ratio	0.88
Debt/Eq	2.18
LT Debt/Eq	1.60
Option/Short	Yes / Yes

EPS (ttm)	0.60
EPS next Y	3.08
EPS next Q	0.72
EPS this Y	-30.80%
EPS next Y	51.92%
EPS next 5Y	5.52%
EPS past 3/5Y	- -
Sales past 3/5Y	5.12% 0.78%
EPS Y/Y TTM	532.66%
Sales Y/Y TTM	4.40%
EPS Q/Q	-303.54%
Sales Q/Q	-1.38%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	-61.39% 3.02%

Insider Own	4.90%
Insider Trans	-1.69%
Inst Own	25.04%
Inst Trans	6.06%
ROA	1.77%
ROE	9.68%
ROIC	3.51%
Gross Margin	52.52%
Oper. Margin	18.83%
Profit Margin	4.07%
SMA20	1.66%
SMA50	5.91%
SMA200	19.39%
Trades

Shs Outstand	1.17B
Shs Float	1.11B
Short Float	2.69%
Short Ratio	5.40
Short Interest	29.85M
52W High	42.02 -2.78%
52W Low	16.74 144.03%
Volatility	2.02% 2.67%
ATR (14)	1.09
RSI (14)	59.05
Beta	0.99
Rel Volume	0.07
Avg Volume	5.53M
Volume	20,628

Perf Week	0.32%
Perf Month	3.37%
Perf Quarter	31.01%
Perf Half Y	30.85%
Perf YTD	30.89%
Perf Year	115.11%
Perf 3Y	403.08%
Perf 5Y	302.86%
Perf 10Y	-7.16%
Recom	1.38
Target Price	48.09
Prev Close	40.85
Price	40.85
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-01-26	Initiated	TD Cowen	Buy	$55
Sep-23-26	Initiated	Oppenheimer	Outperform	$50
Sep-09-26	Initiated	Leerink Partners	Outperform	$45
Dec-09-25	Initiated	Barclays	Overweight	$35
Dec-05-25	Initiated	Scotiabank	Sector Outperform	$35
Jun-06-25	Initiated	Goldman	Buy	$24
May-28-25	Initiated	Truist	Buy	$25
May-12-25	Upgrade	JP Morgan	Neutral → Overweight	$23
Jul-10-24	Upgrade	Argus	Hold → Buy	$20
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral	$14
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight	$12 → $19
Jan-23-24	Upgrade	Jefferies	Hold → Buy	$10 → $14
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral	$8 → $12
Dec-18-23	Initiated	HSBC Securities	Buy	$13
Nov-27-23	Upgrade	UBS	Neutral → Buy	$11 → $13
Jul-06-23	Upgrade	UBS	Sell → Neutral	$7 → $8
May-25-23	Initiated	Morgan Stanley	Equal-Weight	$10
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold	$10 → $12
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight	$11 → $10

Show Previous Ratings

Oct-20-26 08:00AM	UEG Week: Teva and Sanofi's Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn's Disease (GlobeNewswire)
Oct-12-26 05:45PM	Teva to Host R&D Day on Wednesday, November 11 in New York City (GlobeNewswire)
07:48AM	FDA approves Tevas monthly injection of olanzapine for schizophrenia (Pharmaceutical Technology)
Oct-09-26 01:50PM	TEVA Stock Hits Fresh 52-Week High As FDA Approves Monthly Schizophrenia Shot (Stocktwits)
08:43AM	Teva climbs premarket as FDA approves once-monthly schizophrenia treatment (Investing.com)
07:00AM	Loading…
07:00AM	Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia (GlobeNewswire)
Oct-02-26 08:00AM	Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome (GlobeNewswire)
08:00AM	Journal of Child Neurology Publishes Review Highlighting Dopamine's Role in Tourette Syndrome and Ecopipam's Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients (GlobeNewswire)
Oct-01-26 09:38AM	Exxon Mobil downgraded, BP upgraded: Wall Street's top analyst calls (The Fly)
04:30AM	Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates (Business Wire)
Sep-30-26 04:32PM	TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness (GlobeNewswire)
Sep-28-26 04:00PM	Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA (denosumab-adet), a Biosimilar to Xgeva (denosumab) (GlobeNewswire)
Sep-23-26 04:45PM	Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET (GlobeNewswire)
04:45PM	Teva Releases Q3 2026 Aide Memoire (GlobeNewswire)
09:49AM	Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls (The Fly)
04:32PM	Loading…
Sep-18-26 04:32PM	New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients (GlobeNewswire)
04:31PM	Teva Highlights New Real-World Data Showing UZEDY (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs (GlobeNewswire)
04:30PM	Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults (GlobeNewswire)
Sep-16-26 11:53AM	Most Active Options Report: FPS, TEVA, AFL (Schaeffer's Research)
08:00AM	Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care (GlobeNewswire)
Sep-14-26 04:39PM	Teva CEO on the companys NYSE debut and what's next (Yahoo Finance Video)
09:03AM	Temporal Raises $550 Million in Series E Round: NYSE Content Update (PR Newswire)
08:03AM	Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy (GlobeNewswire)
Sep-10-26 06:04AM	Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes (GlobeNewswire)
Sep-07-26 03:53AM	Teva Announces Launch of Offering of Senior Notes (GlobeNewswire)
Sep-04-26 11:30AM	S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline (GlobeNewswire)
Sep-03-26 02:29PM	Outperforming Pharma Stock Still Has Upside Potential (Schaeffer's Research)
Sep-02-26 01:22PM	Tevas mAb shows benefit in celiac disease study (Clinical Trials Arena)
07:03AM	Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential (GlobeNewswire)
06:12AM	Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute (BioPharma Dive)
04:30PM	Loading…
Sep-01-26 04:30PM	Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September (GlobeNewswire)
08:14AM	Mid-cap biotechs join Trumps latest round of drug pricing deals (BioPharma Dive)
08:05AM	Trump lines up MFN deals with nine mid-size pharmas on drug pricing push (Pharmaceutical Technology)
Aug-31-26 09:59PM	Trump's Pharma Pricing Deal Expands as Healthcare Stocks Keep Climbing (BeInCrypto)
06:43PM	$19.6B Infusion In US Plants With Lower Drug Prices: White Houses Deal With Mid-size Drugmakers (Stocktwits)
05:52PM	Trump Announces Drug Pricing Deals with Teva, 8 Other Companies (Barrons.com)
04:07PM	Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S. (GlobeNewswire)
03:34PM	Trump Strikes Medicaid Drug Price Deals With Nine Pharma Firms (Bloomberg)
06:32AM	Teva Pharmaceuticals to acquire BioXcel assets for up to $125m (Pharmaceutical Technology)
Aug-28-26 06:17AM	Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy (GlobeNewswire)
Aug-19-26 06:15PM	AUPH Stock Rallies 6% After-Hours Heres Why (Stocktwits)
08:30AM	U.S. FDA Accepts Teva's New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome (GlobeNewswire)
Aug-11-26 08:00AM	Moody's Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy (GlobeNewswire)
Aug-01-26 11:17PM	Israeli strikes kill at least four in Gaza despite Trump ceasefire breakthrough (Investing.com)
Jul-29-26 07:58PM	Teva CEO on Drug Pipeline, Direct Listing on NYSE (Bloomberg) +9.60%
03:03PM	Teva Pharmaceutical Industries Ltd (TEVA) Q2 2026 Earnings Call Highlights: Strong Innovative ... (GuruFocus.com)
01:22PM	Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views (Investor's Business Daily)
09:43AM	Teva Shares Climb as Revenue Beat and Innovative Drug Growth Offset Earnings Miss (InvestorsHub)
07:42AM	UZEDY: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook (Business Wire)
07:24AM	Medincell: UZEDY: Record Q2 Net Sales of $77M, Up 43% YoY; Teva Raises 2026 Outlook (Business Wire)
07:00AM	Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy (GlobeNewswire)
03:30AM	It is okay not to be okay: NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness (Fortune)
Jul-28-26 05:46PM	Teva Stock Is Rebounding. Its Drug Pipeline Holds the Key to Growth. (Barrons.com)
Jul-23-26 01:27PM	Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat (Barrons.com)
Jul-21-26 05:09PM	Hoka Expected to Drive First Quarter Earnings Results for Deckers, Analysts Say (Footwear News) -8.39% +6.16%
Jul-16-26 08:32AM	Why is Cathie Wood's ARK Fund Backing this Israeli Innovator? (NASDAQ: MDWD) (FinanceWire)
Jul-10-26 06:31AM	Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar (Pharmaceutical Technology)
Jul-09-26 08:30AM	Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus (ocrelizumab) for Multiple Sclerosis (GlobeNewswire)
Jul-08-26 06:57AM	Teva draws up mid-stage study plans for vitiligo asset on Phase Ib success (Clinical Trials Arena)
Jul-07-26 07:00AM	Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results (GlobeNewswire)
Jun-18-26 05:00PM	Teva Releases Q2 2026 Aide Memoire (GlobeNewswire)
04:57PM	Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome (GlobeNewswire)
04:30PM	Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET (GlobeNewswire)
Jun-17-26 12:39PM	Vedana debuts with $46m to progress migraine therapies (Pharmaceutical Technology)
Jun-16-26 09:00PM	Medincell SA (STU:MEB) Full Year 2026 Earnings Call Highlights: Strategic Growth and Challenges (GuruFocus.com)
Jun-10-26 12:03PM	Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy (GlobeNewswire)
Jun-08-26 08:00AM	Teva's Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care (GlobeNewswire)
Jun-05-26 11:30AM	Teva Presents New Data on AUSTEDO (deutetrabenazine) tablets and AUSTEDO XR (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea (GlobeNewswire) +12.69%
Jun-04-26 02:00PM	Amneal Pharmaceuticals gets FDA approval for romidepsin injection solution (Proactive) -7.58%
10:25AM	Amneal Pharmaceuticals Advances After Securing FDA Clearance for Cancer Treatment (AMRX) (InvestorsHub)
08:30AM	Teva Expands European biosimilars portfolio with launch of AHZANTIVE (aflibercept) biosimilar to Eylea (GlobeNewswire)
Jun-01-26 04:30PM	Teva to Present at the Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-21-26 12:30PM	The European Medicines Agency Accepts Teva's Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-'749) for the Treatment of Schizophrenia in Adults (GlobeNewswire)
May-18-26 08:30AM	Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution (GlobeNewswire)
08:00AM	Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact (GlobeNewswire)
May-15-26 04:52AM	Former Ovid CEO Dr. Jeremy Levins rallying cry for biotech (Pharma Voice)
May-04-26 04:30PM	Teva to Present at the BofA Securities Health Care Conference (GlobeNewswire)
Apr-30-26 08:30AM	Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets (GlobeNewswire)
07:01AM	Teva signs off $900m Emalex buyout amid strategic pipeline boosting ploy (Pharmaceutical Technology)
03:05AM	Teva Pharmaceutical Industries Ltd (TEVA) Q1 2026 Earnings Call Highlights: Strong Innovative ... (GuruFocus.com)
Apr-29-26 10:10AM	Teva Surges As Its New Growth Strategy Hits A Key Inflection Point (Investor's Business Daily) +11.89%
07:53AM	Teva nabs experimental Tourette drug in $700M Emalex buyout (BioPharma Dive)
07:39AM	Medincell - UZEDY: Q1 2026 Net Sales Reached $63M, Up 62% Year-on-Year (Business Wire)
07:00AM	Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution (GlobeNewswire)
06:30AM	Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy (GlobeNewswire)
Apr-20-26 10:47AM	Novo's Once-Daily Sickle Cell Pill Hits Milestone. A Smaller Rival Is Sinking 24%. (Barrons.com)
Apr-15-26 08:00AM	Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners (GlobeNewswire)
Apr-14-26 08:00AM	Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics (GlobeNewswire)
Mar-31-26 10:17AM	Immunic appoints biopharmaceutical executive Jon Congleton to board (Proactive) +6.24%
07:45AM	Teva receives FDA approval for Prolia biosimilar (Pharmaceutical Technology)
07:45AM	Blackstone closes largest ever private funding investment round at $6.3bn (Pharmaceutical Technology)
Mar-30-26 08:00AM	Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair (omalizumab) (GlobeNewswire)
Mar-19-26 04:30PM	Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026 (GlobeNewswire)
04:30PM	Teva Releases Q1 2026 Aide Memoire (GlobeNewswire)
Mar-12-26 02:19AM	Is Deckers Outdoor Stock Underperforming the Nasdaq? (Barchart)
Mar-06-26 07:44PM	Analyst Report: Teva Pharmaceutical Industries Limited (Morningstar Research)
Mar-05-26 08:29AM	Corcept's Korlym Drives its 2025 Revenue Surge: What's Ahead? (Zacks)
03:57AM	Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's (Zacks)
Mar-04-26 09:42AM	3 Generic Drug Stocks to Watch Despite Industry Headwinds (Zacks)
06:57AM	Blackstone puts $400M into Teva, Sanofi gut disease drug (BioPharma Dive)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Savage Brian	Interim Chief Legal Officer	Sep 18 '26	Option Exercise	34.70	4,503	156,254	15,842	Sep 22 05:01 PM
Savage Brian	Interim Chief Legal Officer	Sep 18 '26	Sale	38.85	7,342	285,215	8,500	Sep 22 05:01 PM
MIGNONE ROBERTO	Director	Sep 18 '26	Sale	39.06	367,600	14,356,802	0	Sep 22 04:21 PM
Savage Brian	Officer	Sep 18 '26	Proposed Sale	38.85	7,028	273,062		Sep 21 06:40 AM
Bridger Management, LLC (1)	Shareholder	Sep 18 '26	Proposed Sale	39.19	367,600	14,406,244		Sep 18 05:00 PM
Weiss Amir	Chief Accounting Officer	Aug 21 '26	Option Exercise	19.61	2,500	49,025	15,571	Aug 25 04:05 PM
Weiss Amir	Chief Accounting Officer	Aug 21 '26	Sale	37.62	9,445	355,301	13,071	Aug 25 04:05 PM
Satchi-Fainaro Ronit	Director	Aug 21 '26	Sale	37.25	415	15,459	111,986	Aug 25 04:03 PM
Lippman Evan	EVP, Business Development	Aug 17 '26	Sale	36.57	18,600	680,291	25,591	Aug 19 04:00 PM
Lippman Evan	Officer	Aug 17 '26	Proposed Sale	36.57	18,600	680,291		Aug 17 04:00 PM
Zaks Tal Zvi	Director	Aug 05 '26	Sale	34.87	17	593	73,247	Aug 10 06:07 AM
Jover Placid	See "Remarks"	Aug 03 '26	Sale	34.88	12,827	447,351	6,774	Aug 05 04:04 PM
Hughes Eric A	See "Remarks"	Aug 03 '26	Sale	34.88	25,578	892,051	134,877	Aug 05 04:02 PM
Hughes Eric A	Executive VP Global R&D and Ch	Aug 03 '26	Proposed Sale	34.88	25,578	892,051		Aug 03 04:01 PM
Jover Placid	Executive VP, Chief HR Officer	Aug 03 '26	Proposed Sale	34.88	12,827	447,351		Aug 03 04:00 PM
Shields Matthew	EVP, Global Operations	Jun 18 '26	Sale	32.19	9,989	321,547	0	Jun 22 04:00 PM
Shields Matthew	Officer	Jun 18 '26	Proposed Sale	32.19	9,989	321,547		Jun 18 04:14 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Jun 11 '26	Sale	34.10	106,563	3,633,308	65,621	Jun 16 08:28 AM
Kalif Eliyahu Sharon	Officer	Jun 11 '26	Proposed Sale	34.10	106,563	3,633,305		Jun 11 04:00 PM
Francis Richard D	President and CEO	Jun 05 '26	Sale	34.35	6,153	211,356	1,177,529	Jun 08 04:01 PM
Francis Richard D	Officer	Jun 05 '26	Proposed Sale	34.35	6,153	211,356		Jun 05 04:00 PM
Shields Matthew	EVP, Global Operations	Jun 03 '26	Sale	32.87	16,195	532,330	9,989	Jun 04 04:00 PM
Shields Matthew	Officer	Jun 03 '26	Proposed Sale	32.87	16,195	532,330		Jun 03 03:59 PM
Lippman Evan	EVP, Business Development	May 14 '26	Sale	35.58	41,658	1,482,367	6,095	May 18 04:02 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	May 14 '26	Sale	35.61	153,251	5,457,375	172,184	May 18 04:00 PM
Lippman Evan	Officer	May 14 '26	Proposed Sale	35.58	41,658	1,482,367		May 14 04:02 PM
Kalif Eliyahu Sharon	Officer	May 14 '26	Proposed Sale	35.61	153,251	5,457,369		May 14 03:59 PM
Weiss Amir	Chief Accounting Officer	May 06 '26	Sale	36.00	10,679	384,444	20,016	May 07 04:03 PM
Daniell Richard	EVP, Europe Commercial	May 05 '26	Sale	35.40	30,000	1,062,000	55,755	May 07 04:01 PM
Daniell Richard	Officer	May 05 '26	Proposed Sale	35.40	30,000	1,062,000		May 05 04:00 PM
Sabag Mark	See "Remarks"	May 01 '26	Sale	34.99	144,180	5,045,118	80,760	May 04 04:02 PM
Fox Christine	EVP, U.S. Commercial	Apr 30 '26	Sale	35.31	21,258	750,620	63,647	May 04 04:00 PM
Sabag Mark	Officer	May 01 '26	Proposed Sale	34.99	144,180	5,045,123		May 04 08:12 AM
Christine Fox	Officer	Apr 30 '26	Proposed Sale	35.31	21,258	750,633		Apr 30 04:40 PM
Sabag Mark	See "Remarks"	Mar 17 '26	Sale	30.14	62,102	1,871,816	224,940	Mar 19 04:01 PM
Sabag Mark	Officer	Mar 17 '26	Proposed Sale	30.14	62,102	1,871,815		Mar 17 04:15 PM
Francis Richard D	President and CEO	Mar 05 '26	Sale	31.67	20,025	634,160	1,170,639	Mar 09 04:18 PM
Fox Christine	EVP, U.S. Commercial	Mar 05 '26	Sale	31.67	7,924	250,940	84,905	Mar 09 04:16 PM
Hughes Eric A	See "Remarks"	Mar 05 '26	Sale	31.67	9,533	301,895	107,711	Mar 09 04:14 PM
Daniell Richard	EVP, Europe Commercial	Mar 05 '26	Sale	31.67	17,295	547,705	85,755	Mar 09 04:12 PM
Jover Placid	See "Remarks"	Mar 05 '26	Sale	31.67	14,150	448,108	6,774	Mar 09 04:10 PM
Savage Brian	Interim Chief Legal Officer	Mar 05 '26	Sale	31.67	1,127	35,690	10,914	Mar 09 04:09 PM
Shields Matthew	EVP, Global Operations	Mar 05 '26	Sale	31.67	17,295	547,705	9,989	Mar 09 04:05 PM
Francis Richard D	President and CEO	Mar 04 '26	Sale	32.46	23,393	759,442	1,148,212	Mar 06 04:19 PM
Daniell Richard	EVP, Europe Commercial	Mar 04 '26	Sale	32.66	91,345	2,983,517	85,755	Mar 06 04:17 PM
Hughes Eric A	See "Remarks"	Mar 04 '26	Sale	32.46	11,277	366,102	97,590	Mar 06 04:09 PM
Fox Christine	EVP, U.S. Commercial	Mar 04 '26	Sale	32.46	9,098	295,362	75,010	Mar 06 04:05 PM
Savage Brian	Interim Chief Legal Officer	Mar 04 '26	Sale	32.46	2,675	86,843	6,181	Mar 06 04:03 PM
Shields Matthew	Officer	Mar 05 '26	Proposed Sale	31.67	17,295	547,705		Mar 05 05:49 PM
Jover Placid	Officer	Mar 05 '26	Proposed Sale	31.67	14,150	448,108		Mar 05 05:43 PM
Savage Brian	Officer	Mar 05 '26	Proposed Sale	31.67	1,127	35,690		Mar 05 05:39 PM
Fox Christine	Officer	Mar 05 '26	Proposed Sale	31.67	7,924	250,940		Mar 05 05:32 PM
Francis Richard D	Officer	Mar 05 '26	Proposed Sale	31.67	20,025	634,160		Mar 05 05:26 PM
Hughes Eric A	Officer	Mar 05 '26	Proposed Sale	31.67	9,533	301,895		Mar 05 05:13 PM
Daniell Richard	Officer	Mar 05 '26	Proposed Sale	31.67	17,295	547,705		Mar 05 05:08 PM
Daniell Richard	EVP, Europe Commercial	Mar 03 '26	Sale	32.36	128,985	4,173,942	48,384	Mar 05 04:09 PM
Savage Brian	Interim Chief Legal Officer	Mar 03 '26	Sale	32.36	1,274	41,227	2,926	Mar 05 04:06 PM
Francis Richard D	President and CEO	Mar 03 '26	Sale	32.36	442,935	14,333,332	642,099	Mar 05 04:05 PM
Hughes Eric A	See "Remarks"	Mar 03 '26	Sale	32.36	80,762	2,613,450	12,823	Mar 05 04:01 PM
Fox Christine	Officer	Mar 04 '26	Proposed Sale	32.46	9,908	321,658		Mar 04 05:42 PM
Francis Richard D	Officer	Mar 04 '26	Proposed Sale	32.46	23,393	759,442		Mar 04 05:36 PM
Hughes Eric A	Officer	Mar 04 '26	Proposed Sale	32.46	11,277	366,102		Mar 04 05:28 PM
Daniell Richard	Officer	Mar 04 '26	Proposed Sale	32.66	91,345	2,983,516		Mar 04 05:22 PM
Savage Brian	Officer	Mar 03 '26	Proposed Sale	32.36	1,274	41,227		Mar 03 05:46 PM
Francis Richard D	Officer	Mar 03 '26	Proposed Sale	32.36	442,935	14,333,332		Mar 03 05:34 PM
Hughes Eric A	Officer	Mar 03 '26	Proposed Sale	32.36	80,762	2,613,450		Mar 03 05:25 PM
Daniell Richard	Officer	Mar 03 '26	Proposed Sale	32.36	128,985	4,173,942		Mar 03 05:13 PM
Kalif Eliyahu Sharon	EVP, Chief Financial Officer	Feb 26 '26	Sale	33.64	345,810	11,634,708	57,478	Mar 02 04:01 PM
Kalif Eliyahu Sharon	Officer	Feb 26 '26	Proposed Sale	33.64	345,810	11,634,702		Feb 26 04:11 PM
Francis Richard D	President and CEO	Feb 15 '26	Sale	34.22	447,778	15,324,799	271,783	Feb 18 04:01 PM
Francis Richard D	Officer	Feb 17 '26	Proposed Sale	1.00	447,778	447,778		Feb 18 06:12 AM
Weiss Amir	Chief Accounting Officer	Dec 16 '25	Sale	30.20	12,300	371,504	5,650	Dec 18 04:04 PM
MIGNONE ROBERTO	Director	Dec 16 '25	Sale	30.24	77,400	2,340,646	367,600	Dec 18 04:02 PM
Bridger Management, LLC (1)	Shareholder	Dec 12 '25	Proposed Sale	30.18	150,000	4,527,000		Dec 12 04:17 PM
Daniell Richard	Exec. VP, European Commercial	Dec 09 '25	Option Exercise	18.40	115,468	2,124,542	163,852	Dec 11 04:09 PM
Daniell Richard	Exec. VP, European Commercial	Dec 09 '25	Sale	28.68	115,468	3,311,126	48,384	Dec 11 04:09 PM
Sabag Mark	See "Remarks"	Dec 09 '25	Option Exercise	18.61	118,724	2,209,454	269,720	Dec 11 04:06 PM
Sabag Mark	See "Remarks"	Dec 09 '25	Sale	28.73	216,892	6,230,754	52,828	Dec 11 04:06 PM
Sabag Mark	Officer	Dec 09 '25	Proposed Sale	28.73	216,892	6,230,750		Dec 09 04:03 PM
Daniell Richard	Officer	Dec 09 '25	Proposed Sale	28.68	115,468	3,311,131		Dec 09 04:00 PM
MIGNONE ROBERTO	Director	Nov 26 '25	Sale	26.03	50,000	1,301,505	445,000	Dec 01 04:02 PM
Bridger Management, LLC (1)	Shareholder	Nov 26 '25	Proposed Sale	24.99	50,000	1,249,500		Nov 26 04:02 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 20 '25	Sale	24.78	28,229	699,523	63,647	Nov 24 04:03 PM
Fox Christine	Officer	Nov 20 '25	Proposed Sale	24.78	28,229	699,523		Nov 20 04:19 PM
Fox Christine	EVP, Head of U.S. Commercial	Nov 14 '25	Sale	25.11	30,000	753,321	28,384	Nov 18 04:01 PM
Fox Christine	Officer	Nov 14 '25	Proposed Sale	25.11	30,000	753,321		Nov 14 03:59 PM
MIGNONE ROBERTO	Director	Nov 06 '25	Sale	24.11	200,000	4,821,880	495,000	Nov 10 04:15 PM
Weiss Amir	Chief Accounting Officer	Nov 06 '25	Sale	24.44	12,300	300,564	17,950	Nov 10 04:06 PM

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

PresidentMr. Richard D. Francis

Executive VP & CFOMr. Eliyahu Sharon Kalif

Ph.D.Dr. Eric A. Hughes M.D.

Executive VP of US Commercial & Head of Innovative FranchiseMs. Christine Fox

Executive Vice President of Business DevelopmentMr. Evan Lippman M.B.A.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Teva- Pharmaceutical Industries Ltd

Upgrade your Finviz experience